Abbott India share price today

Abbott India Ltd's share price was ₹27,120.00 at the close on 4 November 2026. It has been falling for 53 weeks. That is 0.4% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹25,030 and ₹30,075, and at that close it sat 41% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Abbott India Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 1 week in a row.

Over the last 11 years the share price moved +458% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: revenue up on a year earlier for 11 quarters in a row (every quarter we can compare), profit up on a year earlier for 11 quarters in a row (every quarter we can compare) and foreign funds (FIIs) raised their stake for 4 quarters in a row.

1. Revenue up on a year earlier for 11 quarters in a row (every quarter we can compare)

   In the June 2026 quarter revenue was ₹1,814 crore, +4.4% on a year earlier.

2. Profit up on a year earlier for 11 quarters in a row (every quarter we can compare)

   In the June 2026 quarter profit was ₹429 crore, +17.2% on a year earlier.

3. Foreign funds (FIIs) raised their stake for 4 quarters in a row

   From 0.2% to 0.4% of the company by the September 2026 quarter.

For April to June 2026 (the quarter ended 30 June 2026), Abbott India reported revenue of ₹1,814 crore, up 4.4% from ₹1,738 crore a year earlier, and a profit of ₹429 crore, up 17.2% from ₹366 crore.

Abbott India results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Abbott India closed at ₹27,120.00 on 4 November 2026, down 5.8% from ₹28,785.00 a year earlier (7 November 2025) and up 33.6% over five years. Its highest weekly close since March 2016 was ₹34,940.00 on 27 June 2025.

Abbott India share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

561 weekly closes from 11 March 2016 to 4 November 2026.

4 Nov 2026: Abbott India closed at ₹27,120.00, up 5.8% on the week and up 1.0% on the month. 24 Jul 2026: ex-date for a dividend + special dividend of ₹656 a share.

Earlier

• Results for April to June 2026: Revenue up 4.4% and profit up 17.2% on a year earlier.

Abbott India paid ₹525 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 1.94% at the ₹27,120.00 close on 4 November 2026. The last was a dividend + special dividend of ₹656 a share, ex-date 24 July 2026.

Abbott India dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here.

Yes. Abbott India Ltd paid out 90% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years.

From the NSE corporate-actions record, read 5 November 2026.

Abbott India is on 4 of our India lists: 52 week high & low, Dividend stocks, Small & mid cap stocks and Pharma stocks.

Abbott India Ltd earned ₹429 Cr of net profit in the Jun 2026 quarter, +17.2% on the same quarter a year earlier. That is the 12th quarter in a row of profit growth. Full-year FY26 profit was ₹1,552 Cr. Over 10 years profit has grown 19.8% a year on average. That is 23.6% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹366 Cr.

For the full year, FY26 profit was ₹1,552 Cr (+9.8% on the year before).

Why profit moved: revenue changed +4.4% on a year earlier and the margin moved +3.0 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +11.1% and revenue +6.3%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Abbott India Ltd reported ₹1,814 Cr of revenue in the Jun 2026 quarter, +4.4% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 10.2% a year on average. The last full year, FY26, came in at ₹6,929 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹7,005 Cr.

FY26 revenue was ₹6,929 Cr, +8.1% on the year before.

Recent pace: the last four quarters grew +6.3% on average, against 10.2% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +6.3%, against +8.7% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +11.1%, against +14.2% a year (rolling over).

Abbott India Ltd's operating margin was 29.0% in the Jun 2026 quarter, 3.0 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between 12.0% and 27.0%. The latest quarter is above every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +3.2 percentage points on the year while gross margin changed +2.8 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead.

Over the last 3 years, 85% of Abbott India Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹1,319 Cr of operating cash against ₹1,552 Cr of profit. After ₹59.0 Cr of spending on assets, ₹1,260 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 85% of profit came in as cash: the cash cycle got 11 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner.

What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets.

Abbott India Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 3 days in FY26, down from 14 days in FY21. It spent ₹315 Cr on assets over the last 3 years. Customers take 19 days to pay, and stock sits for 94 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹6,929 Cr, each day of that cycle ties up about ₹19.0 Cr, so roughly ₹57.0 Cr is tied up in the business at any time.

FY26: customers took 19 days to pay and stock sat for 94 days, about 3.1 months of sales sitting as stock, for a full cycle of 3 days, shorter than FY21's 14.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 94 days. Customers pay about 19 days after that. Suppliers are paid at 109 days. Together that makes the 3-day cycle.

Spending on assets: ₹315 Cr over the last 3 years, against ₹219 Cr of depreciation (the yearly wear and tear on existing assets). So it is building a little beyond replacing what wears out. Work still in progress is ₹6.0 Cr (FY26): assets paid for that are not earning yet.

In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean.

Abbott India Ltd's P/E is 35.6×, near the low end of its own history: it has been lower only 12% of the time. Its usual P/E (the middle reading) is 46.5×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks.